6L9.F ViewRay (XETRA) up 2400.00% to €0.025 pre-market 24 Mar 2026: volume spike

We see an outsized pre-market move in 6L9.F stock as ViewRay, Inc. trades at €0.025, a 2,400.00% one-month change driven by thin liquidity and a short-term volume spike. This print follows an open of €0.001 and a prior close of €0.001, with 3,500 shares traded versus an average of 279. We review the balance sheet, recent trading dynamics on XETRA (Germany), and how sector and liquidity conditions explain the price swing. This short briefing focuses on what moved the tape and what traders should watch next.

Pre-market move in 6L9.F stock

ViewRay (6L9.F) opened the pre-market session on XETRA at €0.001 and is printing €0.025 after heavy activity, giving a 3,500 share volume and relative volume of 12.54. One clear driver is the mismatch between current price and the 50-day average (€0.31916) and 200-day average (€2.71739). Small-cap healthcare device names can spike when bid liquidity is thin; here the daily low was €0.001 and the high €0.025.

Trading metrics and valuation context for 6L9.F stock

Market capitalization on the XETRA listing is roughly €207,228,256.00, with 8,289,130,240 shares outstanding. Trailing metrics show EPS of -0.55 and a negative P/E near -0.05, reflecting losses. Price-to-book is low at 0.06, while price-to-sales is 2.36. Cash per share is 0.7524 and the current ratio is 2.36, indicating short-term liquidity. These ratios highlight valuation stress despite a healthy cash buffer per share.

Fundamentals and sector context for 6L9.F stock

ViewRay operates in Medical – Devices inside Healthcare. Revenue per share is 0.5656 while net income per share is -0.5940. R&D intensity is high at 31.73% of revenue, consistent with device innovation. The broader Healthcare sector in Germany shows average P/E near 18.85 and net margin around -22.83% for comparable names, underscoring that ViewRay’s losses are not unique in growth-stage device firms.

Technical and liquidity risks for 6L9.F stock

Technical signals are dominated by extreme dispersion from moving averages: the 50-day at €0.31916 and the 200-day at €2.71739. That gap reflects prolonged weakness and rare spikes. Short-term volatility is high: year high is €4.600 and year low €0.0005, a wide trading range. Low average daily volume (279) makes the stock prone to outsized percentage moves on small trades. Traders should expect large bid-ask spreads and execution risk.

Meyka AI rates 6L9.F with a score out of 100

Meyka AI rates 6L9.F with a score of 61.31/100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects mixed fundamentals, moderate cash per share, and high operational leverage. These grades are not guarantees and we are not financial advisors.

Meyka AI forecast and price-target view for 6L9.F stock

Meyka AI’s forecast model projects a 12-month reference target of €0.08, versus the current €0.025, implying an upside of 220.00%. This model blends fundamentals, liquidity, sector trends, and short-term flow data. Forecasts are model-based projections and not guarantees. Given the stock’s volatile history and low trading depth, any model target should be treated as directional only.

Final Thoughts

Key takeaways for 6L9.F stock: the pre-market print to €0.025 on 24 Mar 2026 reflects a volume-driven spike in a low-liquidity security listed on XETRA. Market cap stands near €207.23m, EPS is -0.55, and price-to-book is 0.06, all signaling a distressed valuation with some cash cushion. Sector pressure and elevated R&D spend are consistent with medical-device peers. Meyka AI’s model projects €0.08 as a 12-month reference, an implied 220.00% upside vs €0.025, but execution and liquidity risk are material. We recommend monitoring confirmed catalysts, bid depth, and official company updates before trading. Use small size and limit orders if you enter a position. Meyka AI, our AI-powered market analysis platform, will update its score and forecast as new data arrives.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.